US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...
Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from ...
US biotech Outlook Therapeutics revealed that the US Food and Drug Administration (FDA) has approved Lytenava ...
Cambridge Antibody Technology is the latest firm to join the Pfizer-Gen network of alliances, which Pfizer initiated in 1995 to expand its biotechnology expertise. As a result, CAT has signed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results